The global oncologic disorders testing industry is exhibiting significant increase, propelled by a rising incidence of lymphoma and other related diseases. Analysts estimate the existing market value to be substantial, with projections indicating a steady compound annual growth percentage (CAGR) over the forecast period. Key trends shaping the aren